TuisBHC • NYSE
add
Bausch Health Companies Inc
Vorige sluiting
$7,88
Dagwisseling
$7,45 - $7,80
Jaarwisseling
$3,96 - $11,46
Markkapitalisasie
2,73 mjd USD
Gemiddelde volume
1,27 m
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 2,51 mjd | 12,15% |
Bedryfskoste | 1,27 mjd | 13,29% |
Netto inkomste | -85,00 m | 77,51% |
Netto winsgrens | -3,39 | 79,93% |
Wins per aandeel | 1,12 | 9,34% |
EBITDA | 866,00 m | 8,93% |
Effektiewe belastingkoers | -338,10% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 719,00 m | -5,39% |
Totale bates | 26,54 mjd | -1,94% |
Totale aanspreeklikheid | 26,78 mjd | -1,89% |
Totale ekwiteit | -242,00 m | — |
Uitstaande aandele | 367,80 m | — |
Prys om te bespreek | -2,47 | — |
Opbrengs op bates | 5,13% | — |
Opbrengs op kapitaal | 6,37% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -85,00 m | 77,51% |
Kontant van bedrywe | 405,00 m | 43,62% |
Kontant van beleggings | -102,00 m | 94,60% |
Kontant van finansiering | -189,00 m | -110,41% |
Netto kontantverandering | 127,00 m | -33,85% |
Beskikbare kontantvloei | 606,75 m | 261,43% |
Meer oor
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
HUB
Gestig
1959
Hoofkwartier
Webwerf
Werknemers
20 270